Text Size

QT Variability Pre and Post Cardioversion (DCCV)

This study has been completed.
Sponsor:
Collaborators:
National Institutes of Health (NIH)
Wake Forest University
Information provided by (Responsible Party):
Dawood Darbar, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00885391
First received: April 20, 2009
Last updated: April 10, 2013
Last verified: April 2013
History of Changes
  Purpose

The purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.


Condition
Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Vanderbilt University:

Enrollment: 219
Study Start Date: January 2007
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Detailed Description:

Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. These are interrelated responses and the extent to which these or other pathophysiologic responses determine QT interval during and after Atrial Fibrillation (AF) is unknown. In this study, the QT variability is related to those potential markers in patients with AF undergoing elective DC-cardioversion.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Cardiology Clinic Hospital inpatient

Criteria

Inclusion Criteria:

  • At least 21 years of age
  • Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center

Exclusion Criteria:

  • Undergoing emergent DC-Cardioversion of atrial fibrillation for hemodynamic instability
  • Undergoing DC-Cardioversion for post-cardiac surgery
  • Dual chamber pacemakers
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00885391

Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-0575
Sponsors and Collaborators
Vanderbilt University
National Institutes of Health (NIH)
Wake Forest University
Investigators
Principal Investigator: Dawood Darbar, M.D., Ph.D., F.A.C.C. Vanderbilt University
  More Information

No publications provided

Responsible Party: Dawood Darbar, Associate Professor of Medicine and Pharmacology, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00885391     History of Changes
Other Study ID Numbers: 060908, RO1-HL085690-01A2
Study First Received: April 20, 2009
Last Updated: April 10, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Vanderbilt University:
Atrial Fibrillation
Cardioversion
Direct Current Cardioversion
QT Interval

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 19, 2013